

Claims

1. A pharmaceutical composition comprising a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 protein and/or a functional fragment thereof, a nucleic acid molecule encoding a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 protein and/or a functional fragment thereof and/or an effector/modulator of said nucleic acid molecule and/or said protein or protein fragment.
2. The composition of claim 1, wherein the composition contains pharmaceutically acceptable carriers, diluents, and/or additives.
3. The composition of claim 1 or 2, wherein the nucleic acid molecule is a mammalian SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 nucleic acid, particularly encoding a human SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 polypeptide and/or a nucleic molecule, which is complementary thereto or a fragment thereof or a variant thereof.
4. The composition of any one of claims 1 to 3, wherein said nucleic acid molecule is selected from the group consisting of
 - (a) a nucleic acid molecule encoding a polypeptide as shown in Table 1, or an isoform, fragment or variant of the polypeptide as shown in Table 1;
 - (b) a nucleic acid molecule which comprises or is the nucleic acid molecule as shown in Table 1;
 - (c) a nucleic acid molecule being degenerate with as a result of the genetic code to the nucleic acid sequences as defined in (a) or (b),
 - (d) a nucleic acid molecule that hybridizes at 50°C in a solution containing 1 x SSC and 0.1% SDS to a nucleic acid molecule as defined in claim 3 or as defined in (a) to (c) and/or a nucleic acid molecule which is complementary thereto;
 - (e) a nucleic acid molecule that encodes a polypeptide which is at least 85%, preferably at least 90%, more preferably at least 95%, more preferably at least 98% and up to 99,6% identical to the human SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8, as defined in claim 3 or to a polypeptide as defined in (a);

- 52 -

(f) a nucleic acid molecule that differs from the nucleic acid molecule of (a) to (e) by mutation and wherein said mutation causes an alteration, deletion, duplication or premature stop in the encoded polypeptide

5

5. The composition of any one of claims 1-4, wherein the nucleic acid molecule is a DNA molecule, particularly a cDNA or a genomic DNA.

10

6. The composition of any one of claims 1-5, wherein said nucleic acid encodes a polypeptide contributing to regulating the metabolism, in particular human metabolism.

7. The composition of any one of claims 1-6, wherein said nucleic acid molecule is a recombinant nucleic acid molecule.

15

8. The composition of any one of claims 1-7, wherein the nucleic acid molecule is a vector, particularly an expression vector.

20

9. The composition of any one of claims 1-6, wherein the polypeptide is a recombinant polypeptide.

10. The composition of claim 9, wherein said recombinant polypeptide is a fusion polypeptide.

25

11. The composition of any one of claims 1-8, wherein said nucleic acid molecule is selected from hybridization probes, primers and anti-sense oligonucleotides.

30

12. The composition of any one of claims 1-11 which is a diagnostic composition.

13. The composition of any one of claims 1-11 which is a therapeutic composition.

35

14. The composition of any one of claims 1-13 for the manufacture of an agent for detecting and/or verifying, for the treatment, alleviation and/or

- 53 -

prevention of pancreatic diseases (e.g. diabetes such as insulin dependent diabetes mellitus, non insulin dependent diabetes mellitus or latent autoimmune diabetes in adults), obesity, metabolic syndrome and/or other metabolic diseases or dysfunctions.

5

15. The composition of any one of claims 1-14 for the manufacture of an agent for the modulation of pancreatic development.

10

16. The composition of any one of claims 1-15 for the manufacture of an agent for the regeneration of pancreatic tissues or cells, particularly pancreatic cells, more particularly beta cells, or exocrine cells.

17. The composition of any one of claims 1-16 for application in vivo.

15

18. The composition of any one of claims 1-16 for application in vitro.

19. The composition of any one of claims 1-18 in combination with at least one further pharmaceutical agent.

20

20. The composition of claim 19 wherein the at least one further pharmaceutical agent is an agent suitable for the prevention and/or treatment of pancreatic diseases and/or obesity and/or metabolic syndrome.

25

21. The composition of claim 19 or 20 wherein the at least one further pharmaceutical agent is an immunosuppressive agent.

30

22. Use of a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 nucleic acid molecule or a polypeptide encoded thereby or a fragment or a variant of said nucleic acid molecule or said polypeptide and/or an effector/modulator of said nucleic acid or polypeptide for the manufacture of a medicament for the treatment of pancreatic diseases (e.g. diabetes such as insulin dependent diabetes mellitus, non insulin dependent diabetes mellitus or latent autoimmune diabetes in adults), obesity, metabolic syndrome and/or other metabolic diseases or dysfunctions for controlling the function of a gene and/or a gene product

35

- 54 -

which is influenced and/or modified by a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 polypeptide.

- 5 23. The use of claim 22 in combination with at least one further pharmaceutical agent.
- 10 24. Use of the SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 nucleic acid molecule or use of a polypeptide encoded thereby, or use of a fragment or a variant of said nucleic acid molecule or said polypeptide, or use of an effector/modulator of said nucleic acid molecule or said polypeptide for identifying substances capable of interacting with a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 polypeptide in vitro and/or in vivo.
- 15 25. A non-human transgenic animal exhibiting a modified expression of a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 polypeptide.
26. The animal of claim 25, wherein the expression of the SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 polypeptide is increased and/or reduced.
- 20 27. A recombinant host cell exhibiting a modified expression of a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 polypeptide, or a recombinant host cell which comprises a nucleic acid molecule as defined in any one of claims 1 to 7.
- 25 28. The cell of claim 27 which is a human cell.
29. A method of identifying a (poly)peptide involved in the regulation of energy homeostasis and/or metabolism in a mammal comprising the steps of
- 30 (a) contacting a collection of (poly)peptides with a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 homologous polypeptide or a fragment thereof under conditions that allow binding of said (poly)peptides;
- (b) removing (poly)peptides which do not bind and
- (c) identifying (poly)peptides that bind to said SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 homologous polypeptide.
- 35

- 55 -

30. A method of screening for an agent which effects/modulates the interaction of a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 polypeptide with a binding target comprising the steps of
- (a) incubating a mixture comprising
 - 5 (aa) a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 polypeptide or a fragment thereof;
 - (ab) a binding target/agent of said SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 polypeptide or fragment thereof; and
 - 10 (ac) a candidate agent under conditions whereby said polypeptide or fragment thereof specifically binds to said binding target at a reference affinity;
 - (b) detecting the binding affinity of said SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 polypeptide or fragment thereof to said binding target to determine an affinity for the agent; and
 - 15 (c) determining a difference between affinity for the agent and reference affinity.
31. A method for screening for an agent, which effects/modulates the activity of a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 polypeptide, comprising the steps of
- 20 (a) incubating a mixture comprising
 - (aa) a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 polypeptide or a fragment thereof; and
 - (ab) a candidate agent
 - 25 under conditions whereby said SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 polypeptide or fragment thereof exhibits a reference activity,
 - (b) detecting the activity of said SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 polypeptide or fragment thereof to determine an activity for the agent; and
 - 30 (c) determining a difference between activity for the agent and reference activity.
32. A method of producing a composition comprising the (poly)peptide identified by the method of claim 29 or the agent identified by the method of claim 30 or 31 with a pharmaceutically acceptable carrier
- 35

- 56 -

and/or diluent.

- 5 33. The method of claim 32 wherein said composition is a pharmaceutical composition for preventing, alleviating or treating of diseases and disorders, including pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome.
- 10 34. Use of a (poly)peptide as identified by the method of claim 29 or of an agent as identified by the method of claim 30 or 31 for the preparation of a pharmaceutical composition (i) for the treatment, alleviation and/or prevention of pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome, (ii) for the modulation of pancreatic development and/or (iii) for the regeneration of pancreatic cells or tissues.
- 15 35. Use of a nucleic acid molecule as defined in any one of claims 1 to 7 or 11 for the preparation of a medicament (i) for the treatment, alleviation and/or prevention of diseases or dysfunctions, including pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome, (ii) for the modulation of pancreatic development and/or (iii) for the regeneration of pancreatic cells or tissues.
- 20 36. Use of a polypeptide as defined in any one of claims 1 to 6, 9 or 10 for the preparation of a medicament (i) for the treatment, alleviation and/or prevention of pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome, (ii) for the modulation of pancreatic development and/or (iii) for the regeneration of pancreatic cells or tissues.
- 25 37. Use of a vector as defined in claim 8 for the preparation of a medicament (i) for the treatment, alleviation and/or prevention of pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome, (ii) for the modulation of pancreatic development and/or (iii) for the regeneration of pancreatic cells or tissues.
- 30 38. Use of a host cell as defined in claim 27 or 28 for the preparation of a medicament (i) for the treatment, alleviation and/or prevention of pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome, (ii) for the modulation of pancreatic development and/or (iii)
- 35

for the regeneration of pancreatic cells or tissues.

39. The use of any one of claims 34-38 wherein the medicament comprises at least one further pharmaceutical agent.

5

40. Use of a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 nucleic acid molecule or of a fragment thereof for the production of a non-human transgenic animal which over- or under-expresses the SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 gene product.

10

41. Kit comprising at least one of

15

- (a) a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 nucleic acid molecule or a functional fragment or an isoform thereof;
- (b) a SF1, SF2, SF3, SF4, SF5, SF6, SF7, or SF8 amino acid molecule or a functional fragment or an isoform thereof;
- (c) a vector comprising the nucleic acid of (a);
- (d) a host cell comprising the nucleic acid of (a) or the vector of (b);
- (e) a polypeptide encoded by the nucleic acid of (a), expressed by the vector of (c) or the host cell of (a);
- (f) a fusion polypeptide encoded by the nucleic acid of (a);
- (g) an antibody, an aptamer or another effector/modulator against the nucleic acid of (a) or the polypeptide of (b) , (e) , or (f) and/or
- (h) an anti-sense oligonucleotide of the nucleic acid of (a).

20

25